Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR - ScienceDirect
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
![The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The](https://www.thelancet.com/cms/attachment/2f9746ff-a56a-4d1f-9fa7-5e6b9f11a6ee/gr1_lrg.jpg "The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The")
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial - The
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
OS of Aspire Study. (7) | Download Scientific Diagram
Efficacy and safety of carfilzomib for the treatment of multiple myeloma: An overview of systematic reviews - ScienceDirect
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Journal of Clinical Oncology
Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram
Optimising Treatment in Relapsed, Refractory Multiple Myeloma | touchONCOLOGY
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
How to Treat High-Risk Myeloma at Diagnosis and Relapse | American Society of Clinical Oncology Educational Book
Elotuzumab - A Closer Look At The ELOQUENT-2 Clinical Trial Results
Cancers | Free Full-Text | A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
